EMMA (Emmaus Life Sciences) Total Payout Ratio: 0.00 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Emmaus Life Sciences Total Payout Ratio?

Emmaus Life Sciences EMMA -0.52% Total Payout Ratio is 0.00 as of Jul. 18, 2026. The stock has 6 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Emmaus Life Sciences's current Total Payout Ratio is 0.00.

Emmaus Life Sciences Total Payout Ratio Related Terms

Emmaus Life Sciences Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Total Payout Ratio Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EMMA vs PTIX, BZYR, RMTG: Total Payout Ratio Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Total Payout Ratio falls into.


Emmaus Life Sciences Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Emmaus Life Sciences's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -7.492
=0.00

Emmaus Life Sciences's Total Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -3.335
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.00 mean?
Emmaus Life Sciences (EMMA) has a Total Payout Ratio of 0.00 as of Jul. 18, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Total Payout Ratio too high?
Emmaus Life Sciences' current Total Payout Ratio is 0.00.
How does Emmaus Life Sciences' Total Payout Ratio compare to PTIX and BZYR?
Emmaus Life Sciences' Total Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 14% above its estimated fair value. The current Total Payout Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Total Payout Ratio is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.